DIMS Institute of Medical Science, Inc.

Developers of Medium-term Carcinogenesis Bioassays in the world. / Contract safety research facility.

Mission

HOME ≫ Screening test of rasH2 mouse ≫

Screening test of ultra-short-term skin carcinogenesis bioassay using rasH2 transgenic mice

How do you solve problem to assess the skin carcinogenesis, when long-term application is difficult due to a high irritation to the skin?

Can you control to consume the test substance?

Can you shorten the application period?

 

We have performed to develop screening test for skin carcinogenesis bioassay, trying to shorten the experimental period, utilizing huge experimental performance, and accumulating many basic data.

 

We completed to develop the ultra-short-term skin carcinogenesis bioassay using rasH2 transgenic mice in collaboration with Central Institute for Experimental Animals (CIEA).

英語版 rasH2超短期発がんスクリーニング試験

This method is capable of detecting the promotion activity of TPA, positive control, by 100% probability. Therefore, this method is excellent as screening of skin carcinogenicity for developing candidates, being able to find the promotion activity of them in relatively short time with low cost.

Japanese

Medium-term Carcinogenesis Bioassay/Safety Assessment for Developing Products

DIMS Institute of Medical Science, Inc.

64 Goura, Nishiazai,
Azai-cho, Ichinomiya,
Aichi 491-0113, Japan

Tel: +81-586-51-1201
Fax: +81-586-51-5634

Company Profile

Mobile site

DIMS Institute of Medical Science, Inc.スマホサイトQRコード

Access to the mobile site of DIMS. from this QR code.